The need for cost-effective choices to treat patients with bipolar 1 disorders including asenapine
Godman, Brian (2015) The need for cost-effective choices to treat patients with bipolar 1 disorders including asenapine. Journal of Medical Economics, 18 (11). pp. 871-873. ISSN 1369-6998 (https://doi.org/10.3111/13696998.2015.1073736)
Preview |
Text.
Filename: Godman_JME_2015_The_need_for_cost_effective_choices_to_treat_patients_with_bipolar_1_disorders.pdf
Accepted Author Manuscript Download (264kB)| Preview |
Abstract
Bipolar 1 disorders (BPD) are a chronic disorder with prevalence rates up to 2.6% of the adult population or higher and appreciable direct and indirect costs. As a result, a concern to health authorities especially given the low age of onset. Consequently, a need to treat BPD patients well and improve their quality of life. Pharmacotherapy includes mood stabilisers and atypical antipsychotics (AAPs). AAPs have different mechanisms of action and side-effects so treatment needs to be tailored. Asenapine in clinical trials is as effective as olanzapine with less metabolic side-effects. Chitnis and colleagues have shown in routine care that asenapine also reduces hospital and emergency room admissions making it cost neutral in BPD, which is of interest to health authorities and clinicians.
-
-
Item type: Article ID code: 53874 Dates: DateEvent2 November 2015Published26 August 2015Published Online8 July 2015AcceptedNotes: This is an Accepted Manuscript of an article published by Taylor & Francis in Journal of Medical Economics on 26 August 2015, available online: http://wwww.tandfonline.com/10.3111/13696998.2015.1073736. Subjects: Medicine > Pharmacy and materia medica Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences Depositing user: Pure Administrator Date deposited: 27 Jul 2015 10:31 Last modified: 11 Nov 2024 11:09 Related URLs: URI: https://strathprints.strath.ac.uk/id/eprint/53874